IL-17E synergizes with EGF and confers<i>in vitro</i>resistance to EGFR-targeted therapies in TNBC cellsYacine Merrouche(Institut Jean Godinot), Jérôme Giustiniani(Inserm)OncotargetJuly 23, 201610.18632/oncotarget.10804Cited by 29SaveCiteExport RISWatch citationsRelated PapersIdentification and Characterization of a Transmembrane Isoform of CD160 (CD160-TM), a Unique Activating Receptor Selectively Expressed upon Human NK Cell Activation|The Journal of Immunology|2009|59IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells|Scientific Reports|2015|56